Centogene N.V. (Nasdaq: CNTG), the essential life science partner
for data-driven answers in rare and neurodegenerative diseases,
today announced its conference schedule for May 2023. CENTOGENE
representatives are attending events in Brazil, the U.S., and
Germany, as well as virtually, and will be available to discuss
Pharma, CRO, and Diagnostic collaboration opportunities. The
Company invites attendees to schedule one-on-one meetings in
advance.
Please see additional details below:
Human Genome Meeting
2023Dates: May 5-6,
2023Location: Windsor Barra Hotel Convention
Center, Rio de Janeiro, BrazilFor information about the Human
Genome Meeting 2023 and to arrange a one-on-one meeting, please
refer to the event webpage
(https://link.centogene.com/428xWyb).
International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) 2023Dates: May 7-10,
2023Location: Boston Convention and Exhibition
Center, Boston, U.S.To learn more about the ISPOR 2023 conference
and set up an in-person meeting with the CENTOGENE team, please
visit the event webpage (https://link.centogene.com/3LAupSu).
The State of Precision
MedicineDate: May 10, 2023, 11:00 a.m. -
3:00 p.m. EDTLocation: VirtualCENTOGENE's
Presentation:Title: The Next Frontier in
Precision Medicine: Learnings From mRNA Therapeutics (Including
Q&A)Speaker: Prof. Peter Bauer, Chief Medical
and Genomic Officer at
CENTOGENEWhen: Wednesday, May 10, 2023, 1:00
- 1:30 p.m. EDTFind out more about The State of Precision Medicine
summit hosted by Inside Precision Medicine and set up a virtual
meeting via the event webpage
(https://link.centogene.com/3HHGNi6).
BIONNALE 2023Dates: May 16-17,
2023Location: Ludwig Erhard Haus, Berlin,
GermanyFor information about the BIONNALE 2023 event and to arrange
a one-on-one meeting, please refer to the event webpage
(https://link.centogene.com/3Vwx9F3).
World Orphan Drug Congress (WODC) USA
2023Dates: May 23-25,
2023Location: Gaylord National Resort and
Convention Center, Washington, D.C., U.S.To learn more about WODC
2023 and set up an in-person meeting with the CENTOGENE team,
please visit the event webpage
(https://link.centogene.com/3AXOg9m).
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with nearly
700,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 260 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target and drug screening, clinical
development, market access and expansion, as well as offering the
CENTOGENE Biodata Licenses and Insight Reports to enable a world
healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward- looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth, execute our business strategy and enter
into new client relationships, our dependency on the rare disease
industry, our ability to manage international expansion, our
reliance on key personnel, our reliance on intellectual property
protection, fluctuations of our operating results due to the effect
of exchange rates, our ability to streamline cash usage, our
continued ongoing compliance with covenants linked to financial
instruments, our requirement for additional financing, or other
factors. For further information on the risks and uncertainties
that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to
CENTOGENE’s business in general, see CENTOGENE’s risk factors set
forth in CENTOGENE’s Form 20-F filed on March 31, 2022, with the
Securities and Exchange Commission (the “SEC”) and subsequent
filings with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and
CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media Contact:
CENTOGENE Ben Legg Corporate
Communications Press@centogene.com
Lennart StreibelInvestor RelationsIR@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2024 to May 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From May 2023 to May 2024